Pathogenesis and treatment of myasthenia gravis.
D000109:Acetylcholine / Q000276:immunology; D000328:Adult; D000818:Animals; D000906:Antibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D051379:Mice; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000209:etiology* / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D010276:Parasympatholytics / Q000627:therapeutic use; D011950:Receptors, Cholinergic / Q000276:immunology; D013934:Thymectomy; D013950:Thymus Gland / Q000276:immunology
D000906:Antibodies; D007166:Immunosuppressive Agents; D010276:Parasympatholytics; D011950:Receptors, Cholinergic; D000109:Acetylcholine